Nanofiber Therapeutics: Revolutionizing Cancer and Inflammation Management is a comprehensive resource designed to enrich knowledge, catalyze scientific advancements, empower patients, and inform policy decisions in nanomedicine. This book leverages the transformative potential of nanotechnology to combat cancer and inflammation, two of the most challenging health conditions today. The book explores the revolutionary potential of nanofiber-based therapeutics, aiming to develop innovative solutions that overcome existing treatment limitations and improve patient outcomes. It bridges the gap between basic scientific research and clinical application, synthesizing the latest advancements in nanofiber technology with insights from preclinical and clinical studies. Covering every facet of nanofiber therapies—from design and production to clinical applications—the book offers a comprehensive overview. It aims to educate healthcare professionals, researchers, policymakers, patients, and the public about the potential of nanofiber therapeutics, empowering stakeholders with the knowledge needed for informed decision-making and interdisciplinary collaboration. By highlighting cutting-edge research and technological innovations, this book inspires scientific curiosity and further research in the field. It fills a gap in the existing literature, laying the groundwork for future research and development, and driving advancements that could transform cancer and inflammation treatment.

Dr. Neeraj Mishra is a Professor at the Amity Institute of Pharmacy, Gwalior, where he has served since July 2019. He has over 20 years of teaching and research experience and more than 150 international and national publications in novel, localized, targeted, and controlled drug delivery systems, including nano- and microparticles for the treatment of breast and colon cancer and neurodegenerative disorders. Dr. Mishra has authored 25 books and 45 book chapters with leading publishers such as Elsevier, Bentham, Springer, and Wiley, and holds five patents (three international and two Indian). His honors include the Distinguished Professor Awards (2019, 2021), Outstanding Scientist Award (2020), and Best Academician Award (2023). In 2025, he was recognized as one of the World’s Top 2% Scientists by Stanford University and Elsevier. Goutam Rath is a professor in the Department of Pharmaceutics at the School of Pharmaceutical Sciences, Siksha 'O' Anusandhan, Bhubaneswan, India. A leading researcher in nanotechnology-based platforms for targeted drug and bioactive delivery, he has earned international recognition for his scientific contributions. He has consistently ranked among the world’s top 2% scientists, as listed by Stanford University, for multiple years. In 2018, he was named among India’s top scientists by Career 360 and recognized by the USFDA for excellence in GMP practices. His work continues to advance pharmaceutical innovation and global health impact. Prof. Rath has successfully led numerous national research projects with cumulative funding exceeding ₹22.2 crores from prestigious agencies like NITI Aayog, DBT, DST, AICTE, UGC, and ICMR. He has authored over 250 peer-reviewed publications with a cumulative impact factor of approximately 1080, an h-index of 59, and over 10,800 citations. Additionally, he has contributed to four textbooks, 20 book chapters, and over 60 scientific presentations. His innovative work is protected by 21 patents, six of which have been commercially transferred, generating revenues of ₹37 lakhs. He currently supervises 85 M.Pharm and 10 Ph.D. scholars, and serves on multiple national expert panels in biotechnology and nanomedicine. Dr. Arun Kumar Singh is an assistant professor in the Department of Pharmacy at Vivekanand Global University, Jaipur. He completed both his MPharm in Pharmaceutics and his PhD at Galgotias University, Greater Noida. His research strengths lie in AI-driven cancer research, nano-formulation, and the intersection of blockchain, IoT, machine learning, big data, and neuroscience with pharmaceutical science. He has authored books and contributed chapters on big data and cancer, and his work includes reviews published in reputable journals. His research appears across publishers such as IOP, Elsevier, CRC Press, and Wiley, reflecting a broad publication record and ongoing contributions to AI-enabled oncology and advanced drug delivery.